Sun Pharma, the leading pharmaceutical company in India, has announced its acquisition of Checkpoint Therapeutics for $355 million. This move is expected to bolster Sun Pharma’s specialty portfolio, particularly with the addition of UNLOXCYT, an FDA-approved medication for advanced skin cancer. The acquisition will not only strengthen Sun Pharma’s position in the oncology treatment market but also expand its global footprint. This strategic decision underscores Sun Pharma’s commitment to growth and innovation in the pharmaceutical industry.